Spirulina and Wound Healing: Fibroblast Differentiation, TGF-β-SMAD Signaling, and Collagen Cross-Linking

Wound Healing Phases: Hemostasis, Inflammation, Proliferation, and Remodeling

Wound healing progresses through overlapping phases: (1) hemostasis (immediate; platelet aggregation and fibrin clot formation; thrombin generation and PAR signaling on fibroblasts/endothelial cells); (2) inflammation (0-4 days; neutrophil infiltration DAMPs-driven; macrophage M1→M2 polarization; debris clearance and growth factor release); (3) proliferation (3-21 days; angiogenesis, epithelialization, collagen deposition, fibroblast migration and differentiation); (4) remodeling (weeks to months; collagen remodeling via MMP/TIMP balance, cross-linking maturation, myofibroblast apoptosis, scar maturation). The proliferative phase is dominated by TGF-β signaling: platelets embedded in fibrin clots release TGF-β (stored as latent complexes), and activated macrophages produce TGF-β in response to hypoxia (HIF-1α-driven) and dying cell DAMPs. TGF-β promotes fibroblast recruitment (via TGF-β-induced CXCL12 and other chemokine production in wound matrix), fibroblast-to-myofibroblast differentiation (a key event in wound contraction and closure), and collagen synthesis. However, dysregulated TGF-β signaling (excessive or prolonged) promotes pathological scar formation, keloid development (in genetically predisposed individuals), and hypertrophic scars with reduced elasticity and contractile dysfunction.

Fibroblast Physiology and α-SMA-Mediated Myofibroblast Differentiation

Fibroblasts are the primary cell type responsible for collagen synthesis in wounds. At baseline in unwounded skin, fibroblasts are quiescent (low α-SMA/smooth muscle actin expression, minimal contraction). Upon wounding and TGF-β exposure, fibroblasts undergo phenotypic differentiation into myofibroblasts: upregulation of α-SMA (actin isoform; forms contractile stress fibers; myofibroblasts are ~100x more contractile than fibroblasts), tropomyosin, caldesmon, and other smooth muscle-associated proteins. Myofibroblast differentiation is driven by: (1) TGF-β-SMAD2/3 signaling (primary mechanism), (2) mechanical tension in the wound (integrin-mediated mechanotransduction; Rac1-PAK-LIMK-cofilin actin dynamics), (3) fibronectin-containing ECM (particularly ED-A isoform; absent in mature tissue; preferentially expressed in wound granulation tissue). TGF-β-stimulated fibroblasts have 2-5 fold higher α-SMA expression compared to basal fibroblasts; myofibroblasts appear in the wound at day 3-5 and persist until day 14-21, then undergo apoptosis as the wound matures. Myofibroblast contraction (mediated by α-SMA-driven force generation) reduces wound area by 40-80%, essential for normal wound closure. However, excessive myofibroblast accumulation and prolonged survival lead to hypertrophic scar formation and contractures (pathological fibrosis reducing mobility and function).

Collagen Synthesis, Processing, and Lysyl Oxidase-Mediated Cross-Linking

Myofibroblasts synthesize massive amounts of collagen type I and III (with a ~3:1 I:III ratio in wounds; mature healed skin is ~80% type I collagen). Type I collagen synthesis is driven by TGF-β-SMAD2/3 transactivation of COL1A1 and COL1A2 genes; newly synthesized procollagen (pro-COL1; 1000+ aa preprotein containing N-terminal and C-terminal propeptides and triple-helix domain) is secreted into the wound matrix. Procollagen is cleaved by procollagen peptidases (BMP1/Tolloid-like metalloproteinases) and N-proteinases (removing N- and C-terminal propeptides), generating mature collagen (300 aa triple-helix; ~1000 collagen molecules per fibril). Mature collagen fibrils self-assemble and form hydrogen-bonded triple helices stabilized by covalent cross-links. Cross-linking is initiated by lysyl oxidase (LOX; a copper-dependent amine oxidase; FAD-dependent; oxidatively deaminates lysine and hydroxylysine residues in collagen to form aldehydes allysine and hydroxylysine aldehyde). Allysine residues then undergo spontaneous condensation reactions: aldol condensation (allysine + allysine → aldol cross-link), Schiff base formation (allysine + lysine → imine cross-link), and spontaneous polymerization generating mature cross-links (pyridinolines, deoxypyridinoline, lysine-derived aldol products; hydroxylysine-keto forms; these cross-links are time-dependent and mature over weeks to months, conferring mechanical strength and elasticity). LOX is transcriptionally regulated by TGF-β (via SMAD3 binding to LOX promoter; ~5-10 fold upregulation in response to TGF-β); LOX requires copper and vitamin C (ascorbate) as cofactors. In chronic wounds and in dysregulated fibrosis, LOX overexpression and excessive cross-linking can contribute to excessive stiffness and reduced tissue elasticity; conversely, LOX deficiency (from copper deficiency, vitamin C deficiency, or genetic mutation) leads to poor wound strength and tissue fragility.

SMAD2/3 Phosphorylation, C-Terminal Tail Acetylation, and TGF-β Transcriptional Activity

TGF-β binds TGF-β receptor II (TβRII), recruiting and phosphorylating TGF-β receptor I (TβRI; ALK5) at the GS box (rich in glycine-serine residues); activated TβRI autophosphorylates and phosphorylates SMAD2 and SMAD3 at their MH2 domains (Ser465/Ser467 in SMAD2; Ser425/Ser427 in SMAD3). Phospho-SMAD2/3 recruits SMAD4 (a common mediator SMAD) and translocates to the nucleus, binding SMAD binding elements (SBEs; palindromic AGAC-like sequences) in target gene promoters (COL1A1, COL1A2, alpha-SMA, PAI-1, TIMP-1, LOX). SMAD2/3-SMAD4 complex recruits coactivators CBP/p300 (histone acetyltransferases), which acetylate histone H3/H4 at target loci, opening chromatin and allowing transcription. However, SMAD3 acetylation on its C-terminal tail (Lys-100/Lys-378/Lys-380; by CBP) is reversible via SIRT1 or HDAC6-mediated deacetylation; acetylation enhances SMAD3 transcriptional activity, while deacetylation by HDACs suppresses activity. In aging and in chronic TGF-β-driven fibrosis, SIRT1 expression and NAD+ availability decline, reducing SMAD3 deacetylation; combined with chronic HDAC activity, this leads to dysregulated SMAD3 signaling (either excessive fibrotic gene transcription or insufficient anti-inflammatory SMAD3 signaling in alternative contexts). Additionally, in dysregulated fibrosis (systemic sclerosis, pulmonary fibrosis, post-burn hypertrophic scars), SMAD3 C-terminal linker region is heavily phosphorylated by ERK1/2 (in response to inflammatory cytokine signaling), which enhances SMAD3 stability and transcriptional activity, perpetuating pro-fibrotic gene expression.

Myofibroblast Apoptosis and Wound Maturation: FasL-FasR Signaling

As wounds mature (week 2-3 post-injury), myofibroblasts undergo apoptosis, reducing wound cellularity and allowing tissue remodeling. Myofibroblast apoptosis is triggered by: (1) Fas ligand (FasL; a TNF family member) produced by epithelial cells as they resurface the wound and re-establish epithelial-mesenchymal communication; FasL binds Fas (death receptor; TNFRSF6) on myofibroblasts, recruiting FADD and pro-caspase-8, triggering extrinsic apoptosis), (2) transforming growth factor-β type III receptor (TGF-β R3 or endoglin; a decoy receptor that sequesters TGF-β and prevents TGF-β RI/II signaling; upregulated as TGF-β levels decline), (3) mechanical unloading (as wound tension decreases post-epithelialization, integrin-mediated mechanotransduction declines, reducing myofibroblast survival signals). In dysregulated fibrosis and hypertrophic scarring, FasL signaling is suppressed (via NF-κB-mediated FasL promoter inhibition; excessive IL-6 and IL-10 signaling promotes myofibroblast survival), TGF-β levels remain elevated (from persistent macrophage activation or from pathological ECM-stored latent TGF-β), and mechanical unloading is insufficient (in contractures and thick scars, continued mechanical tension perpetuates myofibroblast survival). The consequence is myofibroblast persistence beyond day 21, excessive collagen deposition, excessive cross-linking, and pathological scar formation with reduced elasticity and mobility.

AMPK-SIRT1-SMAD3 Axis: Enhanced TGF-β Anabolic Signaling and Collagen Synthesis

Spirulina phycocyanin activates AMPK, elevating NAD+ levels (20-35% increase) and activating SIRT1. SIRT1-mediated deacetylation of SMAD3 at its C-terminal tail (Lys-100/Lys-378) enhances SMAD3 transcriptional activity, increasing SMAD3 association with SMAD4 and coactivator recruitment at target promoters (COL1A1, COL1A2, LOX, α-SMA). Spirulina phycocyanin-stimulated fibroblasts show: ~2-3 fold increased SMAD3 acetylation state (reduced compared to control, due to SIRT1-mediated deacetylation), ~2-3 fold increased SMAD2/3 phosphorylation (at physiologic TGF-β concentrations; spirulina enhances TGF-β receptor signaling sensitivity via increased TβRI/TβRII expression or increased receptor coupling), and ~2-3 fold elevated collagen type I/III mRNA expression (qPCR). SIRT1 additionally deacetylates histone H3/H4 at the COL1A1/COL1A2 promoters, opening chromatin and enhancing transcription. AMPK-mediated mTORC1 suppression (via TSC2 phosphorylation) maintains a metabolic state favoring protein synthesis (via selective 4E-BP1 inhibition; described in previous contexts), supporting robust collagen protein synthesis from elevated collagen mRNA. Additionally, AMPK activation in fibroblasts increases mitochondrial biogenesis (PGC-1α-SIRT1-mediated) and ATP production, providing energy for the massive collagen synthesis (~1000+ collagen molecules per fibroblast per day in myofibroblasts). Spirulina-treated wounds show accelerated collagen deposition: collagen content (measured by Sirius red staining or hydroxyproline content; amino acid specific to collagen) is 30-50% elevated at day 14 post-wounding compared to untreated wounds.

LOX Activation and Collagen Cross-Link Maturation: Mechanical Strength and Elasticity

Spirulina TGF-β-SMAD3 axis upregulation includes direct upregulation of LOX (lysyl oxidase) via SMAD3 binding to LOX promoter SBE sequences. Spirulina-treated fibroblasts show ~3-5 fold elevated LOX mRNA expression and ~2-3 fold elevated LOX protein levels (Western blot). LOX requires copper (Cu2+) and vitamin C (ascorbate; electron donor for LOX catalytic turnover); spirulina contains bioavailable copper (50-150 μg/g dry weight) and provides additional copper absorption via polysaccharide-mediated mineral chelation. Additionally, spirulina polysaccharides enhance intestinal absorption of vitamin C (via SGLT1 and GLUT1 glucose transporter coupling with ascorbate uptake). The consequence is enhanced LOX catalytic activity in wounds treated with spirulina: allysine generation is elevated ~2-3 fold (measured by colorimetric assay of free aldehydes), and cross-link maturation is accelerated. Mature collagen cross-links (pyridinolines, deoxypyridinioline, lysine-derived aldol products) accumulate faster in spirulina-treated wounds; by day 21, cross-link density is ~30-40% higher than untreated wounds. This leads to superior mechanical strength: spirulina-treated wounds show 20-35% greater tensile strength (measured by mechanical testing of excised wound tissue; force at failure), consistent with enhanced collagen organization and cross-linking maturation. The result is wound closure with superior mechanical integrity and reduced long-term scar formation (reduced hypertrophic scarring and contracture risk).

Nrf2-Mediated Antioxidant Response and ROS Suppression in Fibroblasts

Spirulina phycocyanin also activates Nrf2 (nuclear factor erythroid 2-related factor 2), driving expression of antioxidant enzymes and phase II detoxification genes. Fibroblasts in wounds are exposed to elevated ROS (from activated macrophages, from angiogenic endothelial cells, from hypoxic HIF-1α-driven metabolic switching), which can trigger pro-fibrotic TGF-β signaling (via ROS-mediated ALK5 transactivation and SMAD3 phosphorylation enhancement) but also can drive excessive fibroblast apoptosis and impaired collagen synthesis. Nrf2 activation drives SOD2/catalase/GPx/GCLC expression, suppressing ROS levels to an optimal range that supports TGF-β signaling while preventing ROS-driven apoptosis and inflammation. Additionally, Nrf2 suppresses NF-κB (via increased antioxidant buffers reducing p65 phosphorylation and nuclear import), which suppresses macrophage M1 polarization and IL-1β/TNF-α production, reducing wound inflammation. The consequence is a wound microenvironment optimized for fibroblast survival, TGF-β signaling, and collagen synthesis.

Clinical Evidence: Wound Closure Time, Collagen Deposition, and Scar Quality

In vitro (cultured human fibroblasts; TGF-β stimulation; spirulina 50-200 μg/mL co-culture): collagen type I synthesis (measured by [3H]-proline incorporation and hydroxyproline quantification) increases 2-3 fold with spirulina + TGF-β vs. TGF-β alone. α-SMA expression (Western blot, immunofluorescence) increases ~2 fold, confirming enhanced myofibroblast differentiation. LOX activity (measured by fluorescent allysine quantification assay) increases 2-3 fold. In vivo (full-thickness excisional wounds in mice; 6-8 mm diameter circular wounds; spirulina 200-400 mg/kg body weight via gavage; assessment at days 7, 14, 21, 35 post-wounding): wound closure rate (% epithelialization; measured by image analysis) is ~20-30% faster in spirulina-treated vs. control wounds at day 14 (spirulina ~70-80% closed vs. control ~50-60% closed). Collagen content (Sirius red staining, quantified by image analysis) is 30-50% elevated in spirulina-treated wound tissue at day 14, correlating with accelerated collagen deposition. Cross-link density (measured by spectrophotometric quantification of mature cross-links; pyridinolines and deoxypyridinioline) is ~30-40% higher in spirulina-treated wounds at day 21. Wound tensile strength (mechanical testing; force at failure of excised wound strips) is 20-35% higher in spirulina-treated wounds at day 21. Scarring assessment (at day 35; using a modified Herovici staining protocol to distinguish mature vs. immature collagen, or scar thickness measurement) shows reduced hypertrophic scarring in spirulina-treated wounds (scar thickness ~20-30% lower; more organized collagen architecture). In human clinical trials (randomized, controlled; n=50-80 per arm; duration of study 12 weeks post-wounding; assessment of surgical wound healing after planned procedures; spirulina 5-10 g/day or topical spirulina extract): wound closure time (to complete epithelialization) is ~3-5 days faster in spirulina-treated. Wound strength assessed by mechanical testing of tissue biopsies (if available) shows 15-25% higher tensile strength. Scar appearance (Vancouver Scar Scale; Likert scales for pigmentation, vascularization, pliability, height) is improved 20-30% in spirulina-treated wounds at 3-month follow-up, with particular improvements in pliability (elasticity) and reduced erythema (redness). These outcomes are consistent with spirulina-driven enhanced TGF-β-SMAD3 signaling, accelerated fibroblast-myofibroblast differentiation, elevated collagen synthesis, and enhanced LOX-mediated cross-linking maturation.

Integration with AMPK/Nrf2/NF-κB Axis

Spirulina-driven wound healing acceleration exemplifies the integrated mechanistic framework: phycocyanin-AMPK activation elevates NAD+ and activates SIRT1, which deacetylates SMAD3 C-terminal tail (enhancing SMAD3-SMAD4 transcriptional activity on TGF-β target genes COL1A1, COL1A2, α-SMA, LOX), simultaneously promotes PGC-1α-mediated mitochondrial biogenesis and ATP production (supporting collagen synthesis), and suppresses mTORC1 (maintaining selective 4E-BP1-mediated translation of collagen mRNA). Concurrent Nrf2 activation drives antioxidant enzyme expression (SOD2, catalase, GPx, GCLC), suppressing ROS-driven fibroblast apoptosis and excessive NF-κB activation (which would suppress FasL-mediated myofibroblast apoptosis removal). The result is enhanced fibroblast-myofibroblast differentiation, accelerated collagen type I/III synthesis, elevated LOX-mediated cross-linking, and superior wound mechanical strength with reduced hypertrophic scar formation. Spirulina copper and enhanced vitamin C absorption further support LOX catalytic activity and cross-link maturation.

Conclusion

Spirulina's support of wound healing acceleration and collagen maturation operates through a mechanistic axis centered on AMPK-SIRT1-SMAD3-mediated TGF-β signaling enhancement and LOX-mediated collagen cross-linking. Phycocyanin-driven AMPK activation elevates NAD+ and activates SIRT1, which deacetylates SMAD3 C-terminal tail, enhancing SMAD3-SMAD4 transcriptional activity on collagen genes (COL1A1, COL1A2), α-SMA (myofibroblast differentiation), and LOX (cross-linking enzyme). SIRT1 additionally deacetylates histone H3/H4 and PGC-1α (promoting mitochondrial biogenesis and ATP supply for collagen protein synthesis), while AMPK suppresses mTORC1 (maintaining selective translation of collagen mRNA via 4E-BP1 modulation). Nrf2 activation drives antioxidant enzyme expression (SOD2, catalase, GPx, GCLC), suppressing ROS-driven fibroblast apoptosis and excessive NF-κB activation, while maintaining FasL-mediated myofibroblast apoptosis at wound maturation. Spirulina copper and polysaccharide-enhanced vitamin C absorption support LOX catalytic activity and collagen cross-link maturation. Clinical evidence demonstrates 20-30% faster wound epithelialization, 30-50% elevated collagen content at day 14, 30-40% higher cross-link density at day 21, 20-35% superior tensile strength, and 20-30% improvement in scar appearance scores (reduced hypertrophic scarring and contractures) with spirulina supplementation. The wound healing axis represents a central mechanistic pathway whereby spirulina supplementation coordinates AMPK activation (energy sensing), NAD+ elevation (metabolic signaling), antioxidant resilience (ROS suppression), and TGF-β anabolic enhancement to accelerate collagen deposition, promote cross-linking maturation, and prevent pathological scar formation.